Filariasis
Conditions
Interventions
Treatment 1a and 1b
Treatment 2a
Treatment 3a and 3b
Treatment 4a
Treatment 5a and 5b
Treatment 6a
Treatment 7a
Sponsors
University of Buea
The Funding for this trial was received by the German Center for Infection Research DZIF
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) Age 18-55 years (ii) Body weight 50-90 kg (iii) Presence of at least 1 medium-sized onchocercoma detected by palpation (of onchocerciasis patients) (iv) Mf-positive (v) Good general health without any clinical condition requiring medication (vi) No previous history of tuberculosis.
Exclusion criteria
Exclusion criteria: Participants will not be included in the study if any of the following criteria applies: (i) Participants not able to give consent (ii) Participants who are unable to understand the nature, scope, significance and consequences of this clinical trial (iii) Participants taking any concomitant medication (iv) Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure (any member of the rifamycins, doxycycline or any member of the tetracyclines) (v) Laboratory evidence of liver disease (AST, ALT, ?GT, Bilirubin greater than the upper limit of the normal range) and renal disease (serum creatinine greater than 1.5 times upper limit of the normal range).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point will be the proportions of living female worms with normal vs. interrupted embryogenesis assessed by immunohistology and the Wolbachia load assessed by molecular technique (PCR) after 18 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of study participants with absence of microfilariae in the skin or blood, assessed 12 and 24 months compared to pre-treatment. | — |
Countries
Cameroon
Contacts
Public ContactJerome Fru Cho
University of Buea
Outcome results
None listed